Refining, reducing and replacing in vivo WHO-standard preclinical assays of snake venom pathology and antivenom efficacy

The Alistair Reid Venom Research Unit (ARVRU) of the Liverpool School of Tropical Medicine (LSTM) and MicroPharm Ltd. have a long association in the production and delivery of life-saving snake antivenoms for West Africa, which suffers the continent's highest snakebite mortality burden. Antivenom is the mainstay of snakebite treatment and is immunoglobulin purified from the sera of venom-immunised horses and sheep. There is a legal/regulatory requirement to conduct in vivo preclinical efficacy testing of new and existing antivenoms prior to human treatment. These assays carry a 'substantial' severity grading by the UK Home Office.

The objective of this PhD Studentship is to assess whether a cell-based system can be used to replace in vivo preclinical testing, and to determine the extent to which various 3R-modifications can be incorporated into these assays to reduce the numbers of animals and the associated pain, suffering and distress whilst retaining the scientific/regulatory validity of the assays.

Bolton FM, Casewell NR, Al-Abdulla I, Landon J (2014). Production and assessment of ovine antisera for the manufacture of a veterinary adder antivenom. Veterinary Record 174(16):406. doi: 10.1136/vr.102286

Bolton F, Casewell N, Al-Abdulla (2014). Snake antivenom trial. Veterinary Record 174(5):126. doi: 10.1136/vr.g1178

Back to top
PhD Studentship

Grant reference number

NC/K500288/1

Award date:

May 2012 - Apr 2016

Grant amount

£93,063